The FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive ... therapy acts as both a bronchodilator and non-steroidal anti-inflammatory, simultaneously ...

belief that Ohtuvayre's bronchodilator and non-steroidal anti-inflammatory activity can re-define the COPD treatment paradigm." The encouraging sales figures come at a time when treatment options ...

However, hospitalized patients might also benefit from higher doses of systemic steroids initially, followed by an oral taper dose. Conclusion. In the treatment of COPD exacerbations, systemic ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

The drug is significant because it is the first non-steroidal therapy for the ... mechanism already exploited by treatments for asthma, COPD and psoriasis. These include Celgene’s Otezla ...

steroid-free compound in the treatment of Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), and other deadly lung diseases characterized by pulmonary inflammation.